A common occurrence in the age of cancer immunotherapy, immune-related adverse events require multidisciplinary collaboration for investigation and optimal management. Drs. Cassandra and Leonard Calabrese discuss the ever-evolving field and the need for continuing education.
PD-L2 plays a significant part in prostate cancer immune modulation and could be a worthwhile prognostic biomarker as well as an immune checkpoint inhibition target, according to a large genetic analysis.
The Cleveland Clinic Center for Research Excellence in Gynecologic Cancer (CREGC) is a collaborative network for the development of a comprehensive research program to promote the translation of basic science investigation into the clinic.
The No. 4 medical innovation for 2019 offers hope that effective therapies will soon exist for all tumor profiles.